Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation.

Diesch J, Bywater MJ, Sanij E, Cameron DP, Schierding W, Brajanovski N, Son J, Sornkom J, Hein N, Evers M, Pearson RB, McArthur GA, Ganley ARD, O'Sullivan JM, Hannan RD, Poortinga G.

Commun Biol. 2019 Jan 28;2(1):39. doi: 10.1038/s42003-019-0284-y.

PMID:
31924928
2.

Robotic automation of a UHPLC/MS-MS method profiling one-carbon metabolites, amino acids, and precursors in plasma.

Andraos S, Goy M, Albert BB, Kussmann M, Thorstensen EB, O'Sullivan JM.

Anal Biochem. 2020 Jan 3;592:113558. doi: 10.1016/j.ab.2019.113558. [Epub ahead of print]

PMID:
31911045
3.

GWAS on longitudinal growth traits reveals different genetic factors influencing infant, child, and adult BMI.

Couto Alves A, De Silva NMG, Karhunen V, Sovio U, Das S, Taal HR, Warrington NM, Lewin AM, Kaakinen M, Cousminer DL, Thiering E, Timpson NJ, Bond TA, Lowry E, Brown CD, Estivill X, Lindi V, Bradfield JP, Geller F, Speed D, Coin LJM, Loh M, Barton SJ, Beilin LJ, Bisgaard H, Bønnelykke K, Alili R, Hatoum IJ, Schramm K, Cartwright R, Charles MA, Salerno V, Clément K, Claringbould AAJ; BIOS Consortium, van Duijn CM, Moltchanova E, Eriksson JG, Elks C, Feenstra B, Flexeder C, Franks S, Frayling TM, Freathy RM, Elliott P, Widén E, Hakonarson H, Hattersley AT, Rodriguez A, Banterle M, Heinrich J, Heude B, Holloway JW, Hofman A, Hyppönen E, Inskip H, Kaplan LM, Hedman AK, Läärä E, Prokisch H, Grallert H, Lakka TA, Lawlor DA, Melbye M, Ahluwalia TS, Marinelli M, Millwood IY, Palmer LJ, Pennell CE, Perry JR, Ring SM, Savolainen MJ, Rivadeneira F, Standl M, Sunyer J, Tiesler CMT, Uitterlinden AG, Schierding W, O'Sullivan JM, Prokopenko I, Herzig KH, Smith GD, O'Reilly P, Felix JF, Buxton JL, Blakemore AIF, Ong KK, Jaddoe VWV, Grant SFA, Sebert S, McCarthy MI, Järvelin MR; Early Growth Genetics (EGG) Consortium.

Sci Adv. 2019 Sep 4;5(9):eaaw3095. doi: 10.1126/sciadv.aaw3095. eCollection 2019 Sep.

4.

The risk of cardiovascular disease in prostate cancer patients receiving androgen deprivation therapies.

Cardwell CR, O'Sullivan JM, Jain S, Harbinson MT, Cook MB, Hicks BM, Mc Menamin ÚC.

Epidemiology. 2019 Oct 21. doi: 10.1097/EDE.0000000000001132. [Epub ahead of print]

PMID:
31651660
5.

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib.

O'Sullivan JM, Hamblin A, Yap C, Fox S, Boucher R, Panchal A, Alimam S, Dreau H, Howard K, Ware P, Cross NCP, McMullin MF, Harrison CN, Mead AJ.

Blood. 2019 Dec 5;134(23):2107-2111. doi: 10.1182/blood.2019001861. No abstract available.

6.

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.

Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, Brawley CD, Calvert J, Chowdhury S, Cook A, Cross W, Dearnaley DP, Douis H, Gilbert D, Gillessen S, Jones RJ, Langley RE, MacNair A, Malik Z, Mason MD, Matheson D, Millman R, Parker CC, Ritchie AWS, Rush H, Russell JM, Brown J, Beesley S, Birtle A, Capaldi L, Gale J, Gibbs S, Lydon A, Nikapota A, Omlin A, O'Sullivan JM, Parikh O, Protheroe A, Rudman S, Srihari NN, Simms M, Tanguay JS, Tolan S, Wagstaff J, Wallace J, Wylie J, Zarkar A, Sydes MR, Parmar MKB, James ND.

Ann Oncol. 2019 Dec 1;30(12):1992-2003. doi: 10.1093/annonc/mdz396.

7.

Exercise for advanced prostate cancer: a multicomponent, feasibility, trial protocol for men with metastatic castrate-resistant prostate cancer (EXACT).

Brown M, Murphy M, McDermott L, McAneney H, O'Sullivan JM, Jain S, Prue G.

Pilot Feasibility Stud. 2019 Aug 16;5:102. doi: 10.1186/s40814-019-0486-6. eCollection 2019.

8.

Where Do We See Alpha Emitters in Clinical Practice? A Radiation Oncology Perspective.

O'Sullivan JM.

J Med Imaging Radiat Sci. 2019 Dec;50(4S1):S31-S33. doi: 10.1016/j.jmir.2019.06.044. Epub 2019 Aug 16.

PMID:
31427257
9.

Advances in targeted alpha therapy for prostate cancer.

De Vincentis G, Gerritsen W, Gschwend JE, Hacker M, Lewington V, O'Sullivan JM, Oya M, Pacilio M, Parker C, Shore N, Sartor O; Targeted Alpha Therapy Prostate Working Group .

Ann Oncol. 2019 Nov 1;30(11):1728-1739. doi: 10.1093/annonc/mdz270.

10.

Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group.

O'Sullivan JM, Carles J, Cathomas R, Gomez-Iturriaga A, Heinrich D, Kramer G, Ost P, van Oort I, Tombal B.

Eur Urol Oncol. 2019 Mar 25. pii: S2588-9311(19)30031-8. doi: 10.1016/j.euo.2019.02.007. [Epub ahead of print] Review.

PMID:
31411991
11.

Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program.

Saad F, Gillessen S, Heinrich D, Keizman D, O'Sullivan JM, Nilsson S, Miller K, Wirth M, Reeves J, Seger M, Carles J, Heidenreich A.

Clin Genitourin Cancer. 2019 Oct;17(5):348-355.e5. doi: 10.1016/j.clgc.2019.05.012. Epub 2019 May 31.

12.

TNF-α Differentially Regulates Cell Cycle Genes in Promyelocytic and Granulocytic HL-60/S4 Cells.

Jacobson EC, Jain L, Vickers MH, Olins AL, Olins DE, Perry JK, O'Sullivan JM.

G3 (Bethesda). 2019 Aug 8;9(8):2775-2786. doi: 10.1534/g3.119.400361.

13.

Computed Tomography-based Radiomics for Risk Stratification in Prostate Cancer.

Osman SOS, Leijenaar RTH, Cole AJ, Lyons CA, Hounsell AR, Prise KM, O'Sullivan JM, Lambin P, McGarry CK, Jain S.

Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):448-456. doi: 10.1016/j.ijrobp.2019.06.2504. Epub 2019 Jun 26.

PMID:
31254658
14.

von Willebrand factor promotes wound healing.

O'Donnell JS, O'Sullivan JM.

Blood. 2019 Jun 13;133(24):2553-2555. doi: 10.1182/blood.2019001175. No abstract available.

PMID:
31196875
15.

Transcriptional profiling of the zebrafish proximal tubule.

Sander V, Salleh L, Naylor RW, Schierding W, Sontam DM, O'Sullivan JM, Davidson AJ.

Am J Physiol Renal Physiol. 2019 Jun 12. doi: 10.1152/ajprenal.00174.2019. [Epub ahead of print]

PMID:
31188030
16.

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.

Woods BS, Sideris E, Sydes MR, Gannon MR, Parmar MKB, Alzouebi M, Attard G, Birtle AJ, Brock S, Cathomas R, Chakraborti PR, Cook A, Cross WR, Dearnaley DP, Gale J, Gibbs S, Graham JD, Hughes R, Jones RJ, Laing R, Mason MD, Matheson D, McLaren DB, Millman R, O'Sullivan JM, Parikh O, Parker CC, Peedell C, Protheroe A, Ritchie AWS, Robinson A, Russell JM, Simms MS, Srihari NN, Srinivasan R, Staffurth JN, Sundar S, Thalmann GN, Tolan S, Tran ATH, Tsang D, Wagstaff J, James ND, Sculpher MJ.

Eur Urol Oncol. 2018 Dec;1(6):449-458. doi: 10.1016/j.euo.2018.06.004. Epub 2018 Sep 14.

17.

Corrigendum: Functional Urate-Associated Genetic Variants Influence Expression of lincRNAs LINC01229 and MAFTRR.

Leask M, Dowdle A, Salvesen H, Topless R, Fadason T, Wei W, Schierding W, Marsman J, Antony J, O'Sullivan JM, Merriman TR, Horsfield JA.

Front Genet. 2019 Apr 24;10:382. doi: 10.3389/fgene.2019.00382. eCollection 2019.

18.

Hi-C detects novel structural variants in HL-60 and HL-60/S4 cell lines.

Jacobson EC, Grand RS, Perry JK, Vickers MH, Olins AL, Olins DE, O'Sullivan JM.

Genomics. 2020 Jan;112(1):151-162. doi: 10.1016/j.ygeno.2019.05.009. Epub 2019 May 13.

PMID:
31095996
19.

von Willebrand factor sialylation-A critical regulator of biological function.

Ward S, O'Sullivan JM, O'Donnell JS.

J Thromb Haemost. 2019 Jul;17(7):1018-1029. doi: 10.1111/jth.14471. Epub 2019 May 30. Review.

PMID:
31055873
20.

Protocol for the Gut Bugs Trial: a randomised double-blind placebo-controlled trial of gut microbiome transfer for the treatment of obesity in adolescents.

Leong KSW, Jayasinghe TN, Derraik JGB, Albert BB, Chiavaroli V, Svirskis DM, Beck KL, Conlon CA, Jiang Y, Schierding W, Vatanen T, Holland DJ, O'Sullivan JM, Cutfield WS.

BMJ Open. 2019 Apr 20;9(4):e026174. doi: 10.1136/bmjopen-2018-026174.

21.

Advances in understanding the molecular mechanisms that maintain normal haemostasis.

O'Donnell JS, O'Sullivan JM, Preston RJS.

Br J Haematol. 2019 Jul;186(1):24-36. doi: 10.1111/bjh.15872. Epub 2019 Mar 28. Review.

PMID:
30919939
22.

Advances in understanding the molecular mechanisms of venous thrombosis.

Preston RJS, O'Sullivan JM, O'Donnell JS.

Br J Haematol. 2019 Jul;186(1):13-23. doi: 10.1111/bjh.15869. Epub 2019 Mar 24. Review.

PMID:
30906986
23.

Altered gut microbiome after bariatric surgery and its association with metabolic benefits: A systematic review.

Davies NK, O'Sullivan JM, Plank LD, Murphy R.

Surg Obes Relat Dis. 2019 Apr;15(4):656-665. doi: 10.1016/j.soard.2019.01.033. Epub 2019 Feb 7. Review.

PMID:
30824335
24.

Increased galactose expression and enhanced clearance in patients with low von Willebrand factor.

Aguila S, Lavin M, Dalton N, Patmore S, Chion A, Trahan GD, Jones KL, Keenan C, Brophy TM, O'Connell NM, Ryan K, Byrne M, Nolan M, Patel A, Preston RJS, James P, Di Paola J, O'Sullivan JM, O'Donnell JS.

Blood. 2019 Apr 4;133(14):1585-1596. doi: 10.1182/blood-2018-09-874636. Epub 2019 Feb 15.

PMID:
30770394
25.

The Super-Donor Phenomenon in Fecal Microbiota Transplantation.

Wilson BC, Vatanen T, Cutfield WS, O'Sullivan JM.

Front Cell Infect Microbiol. 2019 Jan 21;9:2. doi: 10.3389/fcimb.2019.00002. eCollection 2019. Review.

26.

Functional Urate-Associated Genetic Variants Influence Expression of lincRNAs LINC01229 and MAFTRR.

Leask M, Dowdle A, Salvesen H, Topless R, Fadason T, Wei W, Schierding W, Marsman J, Antony J, O'Sullivan JM, Merriman TR, Horsfield JA.

Front Genet. 2019 Jan 21;9:733. doi: 10.3389/fgene.2018.00733. eCollection 2018. Erratum in: Front Genet. 2019 Apr 24;10:382.

27.

Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation.

Diesch J, Bywater MJ, Sanij E, Cameron DP, Schierding W, Brajanovski N, Son J, Sornkom J, Hein N, Evers M, Pearson RB, McArthur GA, Ganley ARD, O'Sullivan JM, Hannan RD, Poortinga G.

Commun Biol. 2019 Jan 28;2:39. doi: 10.1038/s42003-019-0284-y. eCollection 2019.

28.

Blood group alters platelet binding kinetics to von Willebrand factor and consequently platelet function.

Dunne E, Qi QM, Shaqfeh ES, O'Sullivan JM, Schoen I, Ricco AJ, O'Donnell JS, Kenny D.

Blood. 2019 Mar 21;133(12):1371-1377. doi: 10.1182/blood-2018-06-855528. Epub 2019 Jan 14.

PMID:
30642918
29.

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.

Heidenreich A, Gillessen S, Heinrich D, Keizman D, O'Sullivan JM, Carles J, Wirth M, Miller K, Reeves J, Seger M, Nilsson S, Saad F.

BMC Cancer. 2019 Jan 7;19(1):12. doi: 10.1186/s12885-018-5203-y.

30.

Thirty-seven-year Population-based Study of Colorectal Cancer Rates in Renal Transplant Recipients in Ireland.

Balhareth A, Reynolds IS, Solon JG, Harte EG, Boland F, O'Sullivan JM, Burke JP, Little D, McNamara DA.

Transplant Proc. 2018 Dec;50(10):3434-3439. doi: 10.1016/j.transproceed.2018.07.031. Epub 2018 Aug 9.

PMID:
30577217
31.

Mechanistic Modeling of Radium-223 Treatment of Bone Metastases.

Moreira HMR, Guerra Liberal FDC, O'Sullivan JM, McMahon SJ, Prise KM.

Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1221-1230. doi: 10.1016/j.ijrobp.2018.12.015. Epub 2018 Dec 14.

PMID:
30557674
32.

Type 1 Diabetes Mellitus-Associated Genetic Variants Contribute to Overlapping Immune Regulatory Networks.

Nyaga DM, Vickers MH, Jefferies C, Perry JK, O'Sullivan JM.

Front Genet. 2018 Nov 21;9:535. doi: 10.3389/fgene.2018.00535. eCollection 2018.

33.

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.

Basch EM, Scholz M, de Bono JS, Vogelzang N, de Souza P, Marx G, Vaishampayan U, George S, Schwarz JK, Antonarakis ES, O'Sullivan JM, Kalebasty AR, Chi KN, Dreicer R, Hutson TE, Dueck AC, Bennett AV, Dayan E, Mangeshkar M, Holland J, Weitzman AL, Scher HI.

Eur Urol. 2019 Jun;75(6):929-937. doi: 10.1016/j.eururo.2018.11.033. Epub 2018 Dec 4.

34.

Chromatin interactions and expression quantitative trait loci reveal genetic drivers of multimorbidities.

Fadason T, Schierding W, Lumley T, O'Sullivan JM.

Nat Commun. 2018 Dec 5;9(1):5198. doi: 10.1038/s41467-018-07692-y.

35.

Consensus on molecular imaging and theranostics in prostate cancer.

Fanti S, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I, Chiti A, Clarke N, Eiber M, De Bono J, Fizazi K, Gillessen S, Gledhill S, Haberkorn U, Herrmann K, Hicks RJ, Lecouvet F, Montironi R, Ost P, O'Sullivan JM, Padhani AR, Schalken JA, Scher HI, Tombal B, van Moorselaar RJA, Van Poppel H, Vargas HA, Walz J, Weber WA, Wester HJ, Oyen WJG.

Lancet Oncol. 2018 Dec;19(12):e696-e708. doi: 10.1016/S1470-2045(18)30604-1.

PMID:
30507436
36.

Migration through a small pore disrupts inactive chromatin organization in neutrophil-like cells.

Jacobson EC, Perry JK, Long DS, Olins AL, Olins DE, Wright BE, Vickers MH, O'Sullivan JM.

BMC Biol. 2018 Nov 26;16(1):142. doi: 10.1186/s12915-018-0608-2.

37.

The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer.

O'Sullivan JM, Heinrich D, James ND, Nilsson S, Ost P, Parker CC, Tombal B.

Eur Urol. 2019 Mar;75(3):e51-e52. doi: 10.1016/j.eururo.2018.11.003. Epub 2018 Nov 16. No abstract available.

PMID:
30454914
38.

von Willebrand factor clearance - biological mechanisms and clinical significance.

O'Sullivan JM, Ward S, Lavin M, O'Donnell JS.

Br J Haematol. 2018 Oct;183(2):185-195. doi: 10.1111/bjh.15565. Review.

PMID:
30378120
39.

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O'Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MR; Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators.

Lancet. 2018 Dec 1;392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3. Epub 2018 Oct 21.

40.

Platelets in malaria pathogenesis.

O'Sullivan JM, O'Donnell JS.

Blood. 2018 Sep 20;132(12):1222-1224. doi: 10.1182/blood-2018-08-865618. No abstract available.

PMID:
30237255
41.

A non-coding genetic variant maximally associated with serum urate levels is functionally linked to HNF4A-dependent PDZK1 expression.

Ketharnathan S, Leask M, Boocock J, Phipps-Green AJ, Antony J, O'Sullivan JM, Merriman TR, Horsfield JA.

Hum Mol Genet. 2018 Nov 15;27(22):3964-3973. doi: 10.1093/hmg/ddy295.

PMID:
30124855
42.

Significant gynecological bleeding in women with low von Willebrand factor levels.

Lavin M, Aguila S, Dalton N, Nolan M, Byrne M, Ryan K, White B, O'Connell NM, O'Sullivan JM, Di Paola J, James PD, O'Donnell JS.

Blood Adv. 2018 Jul 24;2(14):1784-1791. doi: 10.1182/bloodadvances.2018017418.

43.

The Impact of Nutritional Interventions in Pregnant Women on DNA Methylation Patterns of the Offspring: A Systematic Review.

Andraos S, de Seymour JV, O'Sullivan JM, Kussmann M.

Mol Nutr Food Res. 2018 Dec;62(24):e1800034. doi: 10.1002/mnfr.201800034. Epub 2018 Aug 7.

PMID:
30035846
44.

The genetic architecture of type 1 diabetes mellitus.

Nyaga DM, Vickers MH, Jefferies C, Perry JK, O'Sullivan JM.

Mol Cell Endocrinol. 2018 Dec 5;477:70-80. doi: 10.1016/j.mce.2018.06.002. Epub 2018 Jun 18. Review.

PMID:
29913182
45.

Myelofibrosis: clinicopathologic features, prognosis, and management.

O'Sullivan JM, Harrison CN.

Clin Adv Hematol Oncol. 2018 Feb;16(2):121-131. Review.

PMID:
29741513
46.

The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial.

Wilson JM, Dearnaley DP, Syndikus I, Khoo V, Birtle A, Bloomfield D, Choudhury A, Graham J, Ferguson C, Malik Z, Money-Kyrle J, O'Sullivan JM, Panades M, Parker C, Rimmer Y, Scrase C, Staffurth J, Stockdale A, Cruickshank C, Griffin C, Hall E; CHHiP Investigators.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1179-1189. doi: 10.1016/j.ijrobp.2018.01.016. Epub 2018 Jan 9.

47.

Identification of human skeletal muscle miRNA related to strength by high-throughput sequencing.

Mitchell CJ, D'Souza RF, Schierding W, Zeng N, Ramzan F, O'Sullivan JM, Poppitt SD, Cameron-Smith D.

Physiol Genomics. 2018 Jun 1;50(6):416-424. doi: 10.1152/physiolgenomics.00112.2017. Epub 2018 Mar 30.

PMID:
29602299
48.

Factors Affecting Gastrointestinal Microbiome Development in Neonates.

Chong CYL, Bloomfield FH, O'Sullivan JM.

Nutrients. 2018 Feb 28;10(3). pii: E274. doi: 10.3390/nu10030274. Review.

49.

Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy.

Denis-Bacelar AM, Chittenden SJ, McCready VR, Divoli A, Dearnaley DP, O'Sullivan JM, Johnson B, Flux GD.

Br J Radiol. 2018 Apr;91(1084):20170795. doi: 10.1259/bjr.20170795. Epub 2018 Feb 5.

50.

A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance.

Ward SE, O'Sullivan JM, Drakeford C, Aguila S, Jondle CN, Sharma J, Fallon PG, Brophy TM, Preston RJS, Smyth P, Sheils O, Chion A, O'Donnell JS.

Blood. 2018 Feb 22;131(8):911-916. doi: 10.1182/blood-2017-06-787853. Epub 2017 Dec 27.

PMID:
29282218

Supplemental Content

Loading ...
Support Center